Pharsight

Drug Patents Expiring in 2032

1. Abilify Mycite Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10517507 OTSUKA Communication system with enhanced partial power source and method of manufacturing same
Jun, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-150) Dec 05, 2017
New Indication(I-746) Jul 27, 2020

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 13 November, 2017

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

ABILIFY MYCITE KIT family patents

Family Patents

2. Abraxane patents expiration

ABRAXANE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9597409 BRISTOL-MYERS Methods of treating cancer
Mar, 2032

(7 years from now)

US9393318 BRISTOL-MYERS Methods of treating cancer
Mar, 2032

(7 years from now)

US9597409

(Pediatric)

BRISTOL-MYERS Methods of treating cancer
Sep, 2032

(8 years from now)

US9393318

(Pediatric)

BRISTOL-MYERS Methods of treating cancer
Sep, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Jun 06, 2023
M(M-14) Dec 06, 2022
New Indication(I-676) Sep 06, 2016
Orphan Drug Exclusivity(ODE) Sep 06, 2020
Orphan Drug Exclusivity(ODE-52) Sep 06, 2020
New Indication(I-658) Oct 11, 2015

Drugs and Companies using PACLITAXEL ingredient

Market Authorisation Date: 07 January, 2005

Treatment: Treatment of lung cancer

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of ABRAXANE before it's drug patent expiration?
More Information on Dosage

ABRAXANE family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Acetadote patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8722738 CUMBERLAND PHARMS Acetycysteine compositions and methods of use thereof
Apr, 2032

(7 years from now)

Drugs and Companies using ACETYLCYSTEINE ingredient

Market Authorisation Date: 23 January, 2004

Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of ACETADOTE before it's drug patent expiration?
More Information on Dosage

ACETADOTE family patents

Family Patents

4. Adlyxin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9511193 SANOFI-AVENTIS US Assembly and indicator for a drug delivery device
Jan, 2032

(7 years from now)

US9440029 SANOFI-AVENTIS US Drive mechanism for a drug delivery device and drug delivery device
Jan, 2032

(7 years from now)

US9072836 SANOFI-AVENTIS US Drive mechanism for a drug delivery device and drug delivery device
Mar, 2032

(7 years from now)

US9821032 SANOFI-AVENTIS US Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
May, 2032

(7 years from now)

US9408893 SANOFI-AVENTIS US Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
Aug, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 27, 2021

Drugs and Companies using LIXISENATIDE ingredient

NCE-1 date: 27 July, 2020

Market Authorisation Date: 27 July, 2016

Treatment: Combination treatment with insulin glargine with or without metformin for improvement of glycemic control in type 2 diabetes mellitus patients; Combination treatment with a glitazone for improvement o...

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

ADLYXIN family patents

Family Patents

5. Adzenys Er patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8709491 NEOS THERAPS INC Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles
Jun, 2032

(8 years from now)

US9265737 NEOS THERAPS INC Pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles
Jun, 2032

(8 years from now)

US9017731 NEOS THERAPS INC Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles
Jun, 2032

(8 years from now)

Drugs and Companies using AMPHETAMINE ingredient

Market Authorisation Date: 15 September, 2017

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage

ADZENYS ER family patents

Family Patents

6. Adzenys Xr-odt patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265737 NEOS THERAPS Pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles
Jun, 2032

(8 years from now)

US8709491 NEOS THERAPS Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles
Jun, 2032

(8 years from now)

US9017731 NEOS THERAPS Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles
Jun, 2032

(8 years from now)

Drugs and Companies using AMPHETAMINE ingredient

Market Authorisation Date: 27 January, 2016

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

How can I launch a generic of ADZENYS XR-ODT before it's drug patent expiration?
More Information on Dosage

ADZENYS XR-ODT family patents

Family Patents

7. Afrezza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8499757 MANNKIND Dry powder inhaler and system for drug delivery
Feb, 2032

(7 years from now)

US8636001 MANNKIND Dry powder inhaler and system for drug delivery
Jul, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 27, 2017

Drugs and Companies using INSULIN RECOMBINANT HUMAN ingredient

Market Authorisation Date: 27 June, 2014

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

AFREZZA family patents

Family Patents

8. Airduo Digihaler patents expiration

AIRDUO DIGIHALER IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808 TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jan, 2032

(7 years from now)

US8978966 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jan, 2032

(7 years from now)

US8714149 TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Feb, 2032

(7 years from now)

US10561808

(Pediatric)

TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jul, 2032

(8 years from now)

US8978966

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jul, 2032

(8 years from now)

US8714149

(Pediatric)

TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Aug, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-61) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025
New Product(NP) Jan 27, 2020

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 12 July, 2019

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

AIRDUO DIGIHALER family patents

Family Patents

9. Airduo Respiclick patents expiration

AIRDUO RESPICLICK IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808 TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jan, 2032

(7 years from now)

US8978966 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jan, 2032

(7 years from now)

US8714149 TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Feb, 2032

(7 years from now)

US10561808

(Pediatric)

TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jul, 2032

(8 years from now)

US8978966

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jul, 2032

(8 years from now)

US8714149

(Pediatric)

TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Aug, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-61) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025
New Product(NP) Jan 27, 2020

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 12 July, 2019

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

AIRDUO RESPICLICK family patents

Family Patents

10. Akynzeo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11312698 HELSINN HLTHCARE Fosnetupitant chloride hydrochloride having improved stability
May, 2032

(7 years from now)

US10717721 HELSINN HLTHCARE Substituted piperaziniums for the treatment of emesis
May, 2032

(7 years from now)

US9908907 HELSINN HLTHCARE Substituted piperaziniums for the treatment of emesis
May, 2032

(7 years from now)

US8426450 HELSINN HLTHCARE Substituted 4-phenyl pyridines having anti-emetic effect
May, 2032

(7 years from now)

US9403772 HELSINN HLTHCARE 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
May, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10208073 HELSINN HLTHCARE Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulator
May, 2032

(7 years from now)

US8895586 HELSINN HLTHCARE Methods of treating emesis
May, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 19, 2023

Drugs and Companies using FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE ingredient

NCE-1 date: 19 April, 2022

Market Authorisation Date: 19 April, 2018

Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

How can I launch a generic of AKYNZEO before it's drug patent expiration?
More Information on Dosage

AKYNZEO family patents

Family Patents

11. Alecensa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9365514 HOFFMANN-LA ROCHE Composition comprising tetracyclic compound
Mar, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-159) Nov 06, 2024
New Indication(I-756) Nov 06, 2020
Orphan Drug Exclusivity(ODE-105) Dec 11, 2022
Orphan Drug Exclusivity(ODE) Nov 06, 2024
New Chemical Entity Exclusivity(NCE) Dec 11, 2020

Drugs and Companies using ALECTINIB HYDROCHLORIDE ingredient

NCE-1 date: 12 December, 2019

Market Authorisation Date: 11 December, 2015

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of ALECENSA before it's drug patent expiration?
More Information on Dosage

ALECENSA family patents

Family Patents

12. Aliqopa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10383876 BAYER HEALTHCARE Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
Mar, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9636344 BAYER HEALTHCARE Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts
Mar, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-155) Sep 14, 2024
Orphan Drug Exclusivity(ODE) Sep 14, 2024
New Chemical Entity Exclusivity(NCE) Sep 14, 2022

Drugs and Companies using COPANLISIB DIHYDROCHLORIDE ingredient

NCE-1 date: 14 September, 2021

Market Authorisation Date: 14 September, 2017

Treatment: Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

ALIQOPA family patents

Family Patents

13. Alkindi Sprinkle patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9717740 ETON Treatment of adrenal insufficiency
Nov, 2032

(8 years from now)

Drugs and Companies using HYDROCORTISONE ingredient

Market Authorisation Date: 29 September, 2020

Treatment: Treatment of adrenal insufficiency

Dosage: GRANULE;ORAL

More Information on Dosage

ALKINDI SPRINKLE family patents

Family Patents

14. Amvuttra patents expiration

AMVUTTRA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9399775 ALNYLAM PHARMS INC RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
Nov, 2032

(8 years from now)

US10570391 ALNYLAM PHARMS INC RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
Nov, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 13, 2027
Orphan Drug Exclusivity(ODE-212) Jun 13, 2029

Drugs and Companies using VUTRISIRAN SODIUM ingredient

NCE-1 date: 13 June, 2026

Market Authorisation Date: 13 June, 2022

Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

AMVUTTRA family patents

Family Patents

15. Aptiom patents expiration

Can you believe APTIOM received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9750747 SUMITOMO PHARMA AM Treatments involving eslicarbazepine acetate or eslicarbazepine
Aug, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-150) Aug 27, 2018
New Indication(I-715) Aug 27, 2018
New Chemical Entity Exclusivity(NCE) Nov 08, 2018

Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient

NCE-1 date: 08 November, 2017

Market Authorisation Date: 08 November, 2013

Treatment: Treatment of partial-onset seizures in a patient suffering from or susceptible to absence seizures

Dosage: TABLET;ORAL

How can I launch a generic of APTIOM before it's drug patent expiration?
More Information on Dosage

APTIOM family patents

Family Patents

16. Aristada patents expiration

ARISTADA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10226458 ALKERMES INC Pharmaceutical compositions comprising sorbitan esters
Mar, 2032

(7 years from now)

US9034867 ALKERMES INC Pharmaceutical compositions comprising sorbitan esters
Nov, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 05, 2020

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

NCE-1 date: 06 October, 2019

Market Authorisation Date: 05 October, 2015

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

ARISTADA family patents

Family Patents

17. Armonair Digihaler patents expiration

ARMONAIR DIGIHALER IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808 TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jan, 2032

(7 years from now)

US8978966 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jan, 2032

(7 years from now)

US8714149 TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Feb, 2032

(7 years from now)

US10561808

(Pediatric)

TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jul, 2032

(8 years from now)

US8978966

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jul, 2032

(8 years from now)

US8714149

(Pediatric)

TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Aug, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jul 09, 2024
New Strength(NS) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025
New Product(NP) Jan 27, 2020

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 08 April, 2022

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

ARMONAIR DIGIHALER family patents

Family Patents

18. Armonair Respiclick patents expiration

ARMONAIR RESPICLICK IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808 TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jan, 2032

(7 years from now)

US8978966 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jan, 2032

(7 years from now)

US8714149 TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Feb, 2032

(7 years from now)

US10561808

(Pediatric)

TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jul, 2032

(8 years from now)

US8978966

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jul, 2032

(8 years from now)

US8714149

(Pediatric)

TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Aug, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jul 09, 2024
New Strength(NS) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025
New Product(NP) Jan 27, 2020

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 08 April, 2022

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

ARMONAIR RESPICLICK family patents

Family Patents

19. Avycaz patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8969566 ALLERGAN Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Jun, 2032

(8 years from now)

US9695122 ALLERGAN Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Jun, 2032

(8 years from now)

US9284314 ALLERGAN Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Jun, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 25, 2020
New Patient Population(NPP) Dec 20, 2025
Generating Antibiotic Incentives Now(GAIN) Feb 25, 2025
New Indication(I-738) Jun 22, 2019

Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient

NCE-1 date: 26 February, 2024

Market Authorisation Date: 25 February, 2015

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

AVYCAZ family patents

Family Patents

20. Azstarys patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9079928 COMMAVE THERAP Methylphenidate-oxoacid conjugates, processes of making and using the same
Jul, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 07, 2026

Drugs and Companies using DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE ingredient

NCE-1 date: 07 May, 2025

Market Authorisation Date: 07 May, 2021

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

AZSTARYS family patents

Family Patents

21. Belbuca patents expiration

Can you believe BELBUCA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9901539 BDSI Transmucosal drug delivery devices for use in chronic pain relief
Dec, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 23, 2018

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE ingredient

Market Authorisation Date: 23 October, 2015

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: FILM;BUCCAL

How can I launch a generic of BELBUCA before it's drug patent expiration?
More Information on Dosage

BELBUCA family patents

Family Patents

22. Belviq patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9169213 EISAI INC Method of weight management
Dec, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 27, 2017

Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient

NCE-1 date: 27 June, 2016

Market Authorisation Date: 27 June, 2012

Treatment: Use of belviq (lorcaserin hydrochloride) for chronic weight management by treating obesity in patients on a reduced-calorie diet and who have achieved a greater than or equal to 5% weight loss by week...

Dosage: TABLET;ORAL

How can I launch a generic of BELVIQ before it's drug patent expiration?
More Information on Dosage

BELVIQ family patents

Family Patents

23. Belviq Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9169213 EISAI INC Method of weight management
Dec, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 27, 2017

Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient

NCE-1 date: 27 June, 2016

Market Authorisation Date: 15 July, 2016

Treatment: Use of lorcaserin hydrochloride for chronic weight management by treating obesity in patients on a reduced-calorie diet and who have achieved a greater than or equal to 5% weight loss by week 12 of tr...

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of BELVIQ XR before it's drug patent expiration?
More Information on Dosage

BELVIQ XR family patents

Family Patents

24. Bijuva patents expiration

BIJUVA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11865179 MAYNE PHARMA Progesterone formulations having a desirable PK profile
Nov, 2032

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10052386 MAYNE PHARMA Progesterone formulations
Nov, 2032

(8 years from now)

US8987237 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(8 years from now)

US10675288 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(8 years from now)

US11110099 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(8 years from now)

US8846648 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(8 years from now)

US11103516 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(8 years from now)

US8846649 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(8 years from now)

US8933059 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(8 years from now)

US9114145 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(8 years from now)

US9114146 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(8 years from now)

US8993548 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(8 years from now)

US9301920 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(8 years from now)

US10206932 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(8 years from now)

US11033626 MAYNE PHARMA Progesterone formulations having a desirable pk profile
Nov, 2032

(8 years from now)

US11793819 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(8 years from now)

US11103513 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(8 years from now)

US11166963 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(8 years from now)

US8993549 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(8 years from now)

US11529360 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(8 years from now)

US10806740 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(8 years from now)

US8633178 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(8 years from now)

US9006222 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(8 years from now)

US10639375 MAYNE PHARMA Progesterone formulations
Nov, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 28, 2021

Drugs and Companies using ESTRADIOL; PROGESTERONE ingredient

Market Authorisation Date: 28 December, 2021

Treatment: Treatment of menopause symptoms, including vasomotor symptoms

Dosage: CAPSULE;ORAL

How can I launch a generic of BIJUVA before it's drug patent expiration?
More Information on Dosage

BIJUVA family patents

Family Patents

25. Biktarvy patents expiration

BIKTARVY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8754065 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(8 years from now)

US9296769 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-256) Jun 18, 2026
M(M-82) Feb 24, 2024
M(M-305) Apr 24, 2027
New Indication(I-942) Feb 23, 2027
Orphan Drug Exclusivity(ODE-468) Feb 23, 2031
Orphan Drug Exclusivity(ODE-378) Oct 07, 2028
New Chemical Entity Exclusivity(NCE) Feb 07, 2023
New Patient Population(NPP) Jun 18, 2022

Drugs and Companies using BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 07 February, 2022

Market Authorisation Date: 07 October, 2021

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of BIKTARVY before it's drug patent expiration?
More Information on Dosage

BIKTARVY family patents

Family Patents

26. Bortezomib patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8962572 FRESENIUS KABI USA Bortezomib formulations
Nov, 2032

(8 years from now)

Drugs and Companies using BORTEZOMIB ingredient

Market Authorisation Date: 06 November, 2017

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

BORTEZOMIB family patents

Family Patents

27. Braftovi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9763941 ARRAY BIOPHARMA INC Method of treating melanoma by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
Nov, 2032

(8 years from now)

US9387208 ARRAY BIOPHARMA INC Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
Nov, 2032

(8 years from now)

US10258622 ARRAY BIOPHARMA INC Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate
Nov, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-194) Jun 27, 2025
New Indication(I-928) Oct 11, 2026
Orphan Drug Exclusivity(ODE-445) Oct 11, 2030
New Chemical Entity Exclusivity(NCE) Jun 27, 2023
New Indication(I-826) Apr 08, 2023

Drugs and Companies using ENCORAFENIB ingredient

NCE-1 date: 27 June, 2022

Market Authorisation Date: 27 June, 2018

Treatment: Treatment of melanoma; Braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, a...

Dosage: CAPSULE;ORAL

How can I launch a generic of BRAFTOVI before it's drug patent expiration?
More Information on Dosage

BRAFTOVI family patents

Family Patents

28. Brenzavvy patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8987323 THERACOSBIO Crystalline form of benzylbenzene SGLT2 inhibitor
May, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 20, 2028

Drugs and Companies using BEXAGLIFLOZIN ingredient

NCE-1 date: 20 January, 2027

Market Authorisation Date: 20 January, 2023

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

BRENZAVVY family patents

Family Patents

29. Brixadi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11135215 BRAEBURN Opioid formulations
Jul, 2032

(8 years from now)

US11110084 BRAEBURN Opioid formulations
Jul, 2032

(8 years from now)

US10912772 BRAEBURN Opioid formulations
Jul, 2032

(8 years from now)

US9937164 BRAEBURN Opioid formulations
Jul, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 23, 2026

Drugs and Companies using BUPRENORPHINE ingredient

Market Authorisation Date: 23 May, 2023

Treatment: A method of administering an opioid maintenance treatment comprising buprenorphine; A method of administering an opioid maintenance treatment comprising buprenorphine. a method of treating opioid with...

Dosage: SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

BRIXADI family patents

Family Patents

30. Bunavail patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8703177 BDSI Abuse-resistant mucoadhesive devices for delivery of buprenorphine
Aug, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 06, 2017

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 06 June, 2014

Treatment: NA

Dosage: FILM;BUCCAL

How can I launch a generic of BUNAVAIL before it's drug patent expiration?
More Information on Dosage

BUNAVAIL family patents

Family Patents

31. Cabometyx patents expiration

CABOMETYX's oppositions filed in EPO
Can you believe CABOMETYX received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11298349 EXELIXIS INC Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
Feb, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-227) Jan 14, 2026
New Indication(I-854) Jan 22, 2024
Orphan Drug Exclusivity(ODE-375) Sep 17, 2028
New Indication(I-873) Sep 17, 2024
New Chemical Entity Exclusivity(NCE) Nov 29, 2017
New Indication(I-760) Dec 19, 2020
New Product(NP) Apr 25, 2019
New Indication(I-792) Jan 14, 2022

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

NCE-1 date: 29 November, 2016

Market Authorisation Date: 25 April, 2016

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of CABOMETYX before it's drug patent expiration?
More Information on Dosage

CABOMETYX family patents

Family Patents

32. Caldolor patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9072710 CUMBERLAND PHARMS Injectable ibuprofen formulation
Mar, 2032

(7 years from now)

US9072661 CUMBERLAND PHARMS Injectable ibuprofen formulation
Mar, 2032

(7 years from now)

US11806400 CUMBERLAND PHARMS Injectable ibuprofen formulation
Mar, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-128) Nov 19, 2024
New Patient Population(NPP) May 11, 2026
New Product(NP) Jun 11, 2012
New Dosing Schedule(D-152) Nov 20, 2018

Drugs and Companies using IBUPROFEN ingredient

Market Authorisation Date: 11 June, 2009

Treatment: Methods of making aqueous composition and treating pain, inflammation, fever, patent ductus arteriosis with aqueous composition; Methods of treating pain, inflammation, fever, patent ductus arteriosis...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

CALDOLOR family patents

Family Patents

33. Calquence patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9290504 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors
Jul, 2032

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10239883 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors
Jul, 2032

(8 years from now)

US9758524 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors
Jul, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-175) Oct 31, 2024
Orphan Drug Exclusivity(ODE-274) Nov 21, 2026
New Indication(I-817) Nov 21, 2022
New Chemical Entity Exclusivity(NCE) Oct 31, 2022

Drugs and Companies using ACALABRUTINIB ingredient

NCE-1 date: 31 October, 2021

Market Authorisation Date: 31 October, 2017

Treatment: Treatment of adult patients with chronic lymphocytic leukemia; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy

Dosage: CAPSULE;ORAL

How can I launch a generic of CALQUENCE before it's drug patent expiration?
More Information on Dosage

CALQUENCE family patents

Family Patents

34. Calquence patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9290504 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors
Jul, 2032

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9758524 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors
Jul, 2032

(8 years from now)

US10239883 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors
Jul, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 31, 2022

Drugs and Companies using ACALABRUTINIB MALEATE ingredient

NCE-1 date: 31 October, 2021

Market Authorisation Date: 03 August, 2022

Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination wi...

Dosage: TABLET;ORAL

More Information on Dosage

CALQUENCE family patents

Family Patents

35. Caspofungin Acetate patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9636407 FRESENIUS KABI USA Caspofungin acetate formulations
Dec, 2032

(8 years from now)

Drugs and Companies using CASPOFUNGIN ACETATE ingredient

Market Authorisation Date: 30 December, 2016

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

CASPOFUNGIN ACETATE family patents

Family Patents

36. Cetylev patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8747894 ARBOR PHARMS LLC Effervescent compositions containing N-acetylcysteine
May, 2032

(7 years from now)

US9427421 ARBOR PHARMS LLC Effervescent compositions containing N-acetylcysteine
May, 2032

(7 years from now)

US9561204 ARBOR PHARMS LLC Effervescent compositions containing N-acetylcysteine
May, 2032

(7 years from now)

Drugs and Companies using ACETYLCYSTEINE ingredient

Market Authorisation Date: 29 January, 2016

Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions

Dosage: TABLET, EFFERVESCENT;ORAL

More Information on Dosage

CETYLEV family patents

Family Patents

37. Cometriq patents expiration

COMETRIQ's oppositions filed in EPO
Can you believe COMETRIQ received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9717720 EXELIXIS Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
Feb, 2032

(7 years from now)

US11298349 EXELIXIS Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
Feb, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-33) Nov 29, 2019
Orphan Drug Exclusivity(ODE) Nov 29, 2019
New Chemical Entity Exclusivity(NCE) Nov 29, 2017

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

NCE-1 date: 29 November, 2016

Market Authorisation Date: 29 November, 2012

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

COMETRIQ family patents

Family Patents

38. Contrave patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248123 NALPROPION Methods of providing weight loss therapy in patients with major depression
Jan, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Sep 10, 2017

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 10 September, 2014

Treatment: Use of naltrexone and bupropion for chronic weight management for treating overweight or obesity in patients with major depressive disorder

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of CONTRAVE before it's drug patent expiration?
More Information on Dosage

CONTRAVE family patents

Family Patents

39. Copiktra patents expiration

Can you believe COPIKTRA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE46621 SECURA Processes for preparing isoquinolinones and solid forms of isoquinolinones
May, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11312718 SECURA Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one
Jan, 2032

(7 years from now)

US9840505 SECURA Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof
Jan, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-208) Sep 24, 2025
Orphan Drug Exclusivity(ODE-209) Sep 24, 2025
New Chemical Entity Exclusivity(NCE) Sep 24, 2023

Drugs and Companies using DUVELISIB ingredient

NCE-1 date: 24 September, 2022

Market Authorisation Date: 24 September, 2018

Treatment: For the treatment of patients with follicular lymphoma (fl)

Dosage: CAPSULE;ORAL

More Information on Dosage

COPIKTRA family patents

Family Patents

40. Cotempla Xr-odt patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9072680 NEOS THERAPS INC Compositions comprising methylphenidate complexed with ion-exchange resin particles
Jun, 2032

(8 years from now)

US9089496 NEOS THERAPS INC Compositions comprising methylphenidate complexed with ion-exchange resin particles
Jun, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 19, 2020

Drugs and Companies using METHYLPHENIDATE ingredient

Market Authorisation Date: 19 June, 2017

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

How can I launch a generic of COTEMPLA XR-ODT before it's drug patent expiration?
More Information on Dosage

COTEMPLA XR-ODT family patents

Family Patents

41. Cycloset patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11000522 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(7 years from now)

US9522117 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(7 years from now)

US9700555 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(7 years from now)

US9993474 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(7 years from now)

US8431155 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(7 years from now)

US9192576 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(7 years from now)

US10688094 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(7 years from now)

US8613947 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 05, 2012

Drugs and Companies using BROMOCRIPTINE MESYLATE ingredient

Market Authorisation Date: 05 May, 2009

Treatment: Adjunct to diet exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 13, 2...

Dosage: TABLET;ORAL

More Information on Dosage

CYCLOSET family patents

Family Patents

42. Daybue patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9212204 ACADIA PHARMS INC Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acid
Jan, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-425) Mar 10, 2030
New Chemical Entity Exclusivity(NCE) Mar 10, 2028

Drugs and Companies using TROFINETIDE ingredient

NCE-1 date: 11 March, 2027

Market Authorisation Date: 10 March, 2023

Treatment: Treatment of rett syndrome or a symptom thereof

Dosage: SOLUTION;ORAL

More Information on Dosage

DAYBUE family patents

Family Patents

43. Defitelio patents expiration

DEFITELIO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11746348 JAZZ PHARMS INC Euglobulin-based method for determining the biological activity of defibrotide
Jun, 2032

(8 years from now)

US11236328 JAZZ PHARMS INC Euglobulin-based method for determining the biological activity of defibrotide
Jun, 2032

(8 years from now)

US11085043 JAZZ PHARMS INC Euglobulin-based method for determining the biological activity of defibrotide
Jun, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-112) Mar 30, 2023
Orphan Drug Exclusivity(ODE) Mar 30, 2023
New Chemical Entity Exclusivity(NCE) Mar 30, 2021

Drugs and Companies using DEFIBROTIDE SODIUM ingredient

NCE-1 date: 30 March, 2020

Market Authorisation Date: 30 March, 2016

Treatment: Treatment of adult and pediatric patients with hepatic veno-occlusive disease (vod), also known as sinusoidal obstruction syndrome (sos), with renal or pulmonary dysfunction following hematopoietic st...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

DEFITELIO family patents

Family Patents

44. Descovy patents expiration

DESCOVY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9296769 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(8 years from now)

US8754065 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-285) Sep 28, 2024
Orphan Drug Exclusivity(ODE-284) Sep 28, 2024
Orphan Drug Exclusivity(ODE-457) Jan 07, 2029
New Chemical Entity Exclusivity(NCE) Nov 05, 2020
New Patient Population(NPP) Sep 28, 2020
New Indication(I-812) Oct 03, 2022

Drugs and Companies using EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 06 November, 2019

Market Authorisation Date: 07 January, 2022

Treatment: Treatment of hiv-1 infection; Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of DESCOVY before it's drug patent expiration?
More Information on Dosage

DESCOVY family patents

Family Patents

45. Detectnet patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10159759 RADIOMEDIX Pet tracer for imaging of neuroendocrine tumors
Aug, 2032

(8 years from now)

US10383961 RADIOMEDIX PET tracer for imaging of neuroendocrine tumors
Aug, 2032

(8 years from now)

US11160888 RADIOMEDIX PET tracer for imaging of neuroendocrine tumors
Aug, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 03, 2025
Orphan Drug Exclusivity(ODE-317) Sep 03, 2027

Drugs and Companies using COPPER CU-64 DOTATATE ingredient

NCE-1 date: 03 September, 2024

Market Authorisation Date: 03 September, 2020

Treatment: Use of cu-64 dotatate with positron emission tomography (pet) for localization of somatostatin receptor positive neuroendocrine tumors (nets) in adult patients

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

DETECTNET family patents

Family Patents

46. Dexilant patents expiration

Can you believe DEXILANT received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9233103 TAKEDA PHARMS USA Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy
Mar, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 30, 2012
New Patient Population(NPP) Jul 08, 2019
Pediatric Exclusivity(PED) Jul 30, 2012

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 30 January, 2009

Treatment: Use of dexlansoprazole in patients taking clopidogrel without meaningful cyp2c19 interactions

Dosage: CAPSULE, DELAYED RELEASE;ORAL

How can I launch a generic of DEXILANT before it's drug patent expiration?
More Information on Dosage

DEXILANT family patents

Family Patents

47. Dexycu Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10799642 EYEPOINT PHARMS Dose guides for injection syringe
May, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Feb 09, 2021

Drugs and Companies using DEXAMETHASONE ingredient

Market Authorisation Date: 09 February, 2018

Treatment: NA

Dosage: SUSPENSION;INTRAOCULAR

More Information on Dosage

DEXYCU KIT family patents

Family Patents

48. Dilaudid patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9731082 FRESENIUS KABI USA Drug container
Apr, 2032

(7 years from now)

Drugs and Companies using HYDROMORPHONE HYDROCHLORIDE ingredient

Market Authorisation Date: 16 January, 2020

Treatment: NA

Dosage: INJECTABLE;INJECTION

How can I launch a generic of DILAUDID before it's drug patent expiration?
More Information on Dosage

DILAUDID family patents

Family Patents

49. Dilaudid-hp patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9731082 FRESENIUS KABI USA Drug container
Apr, 2032

(7 years from now)

Drugs and Companies using HYDROMORPHONE HYDROCHLORIDE ingredient

Market Authorisation Date: 16 January, 2020

Treatment: NA

Dosage: INJECTABLE;INJECTION

How can I launch a generic of DILAUDID-HP before it's drug patent expiration?
More Information on Dosage

DILAUDID-HP family patents

Family Patents

50. Duzallo patents expiration

DUZALLO's oppositions filed in EPO
Can you believe DUZALLO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8546436 IRONWOOD PHARMS INC Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof
Feb, 2032

(7 years from now)

Drugs and Companies using ALLOPURINOL; LESINURAD ingredient

Market Authorisation Date: 18 August, 2017

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

DUZALLO family patents

Family Patents

51. Epaned Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8568747 AZURITY Enalapril compositions
Nov, 2032

(8 years from now)

US9855214 AZURITY Enalapril compositions
Nov, 2032

(8 years from now)

US9968553 AZURITY Enalapril compositions
Nov, 2032

(8 years from now)

US8778366 AZURITY Enalapril compositions
Nov, 2032

(8 years from now)

Drugs and Companies using ENALAPRIL MALEATE ingredient

Market Authorisation Date: 13 August, 2013

Treatment: Treatment of heart failure; Method of treating left ventricular dysfunction

Dosage: FOR SOLUTION;ORAL

How can I launch a generic of EPANED KIT before it's drug patent expiration?
More Information on Dosage

EPANED KIT family patents

Family Patents

52. Epclusa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8575135 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(8 years from now)

US8940718 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(8 years from now)

US8921341 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-293) Mar 19, 2027
M(M-264) Jul 14, 2023
Orphan Drug Exclusivity(ODE-376) Jun 10, 2028
M(M-277) Apr 27, 2025
Pediatric Exclusivity(PED) Dec 10, 2028
New Dosing Schedule(D-177) Nov 15, 2022
New Patient Population(NPP) Mar 19, 2023
New Chemical Entity Exclusivity(NCE) Jun 28, 2021
New Strength(NS) Mar 19, 2023

Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient

NCE-1 date: 11 December, 2027

Market Authorisation Date: 19 March, 2020

Treatment: For the treatment of hepatitis c

Dosage: TABLET;ORAL; PELLETS;ORAL

More Information on Dosage

EPCLUSA family patents

Family Patents

53. Epsolay patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9687465 GALDERMA LABS LP Compositions for the treatment of rosacea
Nov, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 22, 2025

Drugs and Companies using BENZOYL PEROXIDE ingredient

Market Authorisation Date: 22 April, 2022

Treatment: Topical treatment of inflammatory lesions of rosacea in adults 18 years of age and older

Dosage: CREAM;TOPICAL

More Information on Dosage

EPSOLAY family patents

Family Patents

54. Evotaz patents expiration

EVOTAZ's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718 BRISTOL Use of solid carrier particles to improve the processability of a pharmaceutical agent
Oct, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 27, 2017

Drugs and Companies using ATAZANAVIR SULFATE; COBICISTAT ingredient

NCE-1 date: 27 August, 2016

Market Authorisation Date: 29 January, 2015

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of EVOTAZ before it's drug patent expiration?
More Information on Dosage

EVOTAZ family patents

Family Patents

55. Evzio patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8627816 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2032

(7 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 03 April, 2014

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

EVZIO family patents

Family Patents

56. Evzio (autoinjector) patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8627816 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2032

(7 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 October, 2016

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

EVZIO (AUTOINJECTOR) family patents

Family Patents

57. Fetzima patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8865937 ABBVIE Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide
May, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-304) Mar 24, 2026
NCE*(NCE*) Jul 25, 2018
M(M-249) Oct 07, 2022

Drugs and Companies using LEVOMILNACIPRAN HYDROCHLORIDE ingredient

Market Authorisation Date: 25 July, 2013

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of FETZIMA before it's drug patent expiration?
More Information on Dosage

FETZIMA family patents

Family Patents

58. Fiasp Flextouch patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9132239 NOVO Dial-down mechanism for wind-up pen
Feb, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Dec 19, 2022
New Product(NP) Sep 29, 2020
M(M-247) Oct 21, 2022

Drugs and Companies using INSULIN ASPART ingredient

Market Authorisation Date: 29 September, 2017

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

FIASP FLEXTOUCH family patents

Family Patents

59. Firdapse patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11274332 CATALYST PHARMS Methods of administering 3,4-diaminopyridine
Jun, 2032

(8 years from now)

US11268128 CATALYST PHARMS Methods of administering 3,4-diaminopyridine
Jun, 2032

(8 years from now)

US11274331 CATALYST PHARMS Methods of administering 3,4-diaminopyridine
Jun, 2032

(8 years from now)

US11060128 CATALYST PHARMS Methods of administering 3,4-diaminopyridine
Jun, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-223) Nov 28, 2025
New Patient Population(NPP) Sep 29, 2025
New Chemical Entity Exclusivity(NCE) Nov 28, 2023

Drugs and Companies using AMIFAMPRIDINE PHOSPHATE ingredient

NCE-1 date: 28 November, 2022

Market Authorisation Date: 28 November, 2018

Treatment: Method of treating lambert-eaton myasthenic syndrome with amifampridine

Dosage: TABLET;ORAL

How can I launch a generic of FIRDAPSE before it's drug patent expiration?
More Information on Dosage

FIRDAPSE family patents

Family Patents

60. Firmagon patents expiration

FIRMAGON's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11766468 FERRING Method of treating prostate cancer with GnRH antagonist
Apr, 2032

(7 years from now)

US9415085 FERRING Method of treating prostate cancer with GnRH antagonist
Apr, 2032

(7 years from now)

US11826397 FERRING Method of treating prostate cancer with GnRH antagonist
Apr, 2032

(7 years from now)

US10695398 FERRING Method of treating prostate cancer with GnRH antagonist
Apr, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 24, 2013

Drugs and Companies using DEGARELIX ACETATE ingredient

NCE-1 date: 24 December, 2012

Market Authorisation Date: 24 December, 2008

Treatment: Treatment of advanced prostate cancer with a reduced likelihood of causing a gonadotrophin releasing hormone agonist side-effect; Method of treating prostate cancer

Dosage: POWDER;SUBCUTANEOUS

How can I launch a generic of FIRMAGON before it's drug patent expiration?
More Information on Dosage

FIRMAGON family patents

Family Patents

61. Genvoya patents expiration

GENVOYA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8754065 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(8 years from now)

US9296769 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718 GILEAD SCIENCES INC Use of solid carrier particles to improve the processability of a pharmaceutical agent
Oct, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Sep 25, 2020
New Dosing Schedule(D-173) Dec 10, 2021
New Chemical Entity Exclusivity(NCE) Nov 05, 2020

Drugs and Companies using COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 06 November, 2019

Market Authorisation Date: 05 November, 2015

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of GENVOYA before it's drug patent expiration?
More Information on Dosage

GENVOYA family patents

Family Patents

62. Gilenya patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9592208 NOVARTIS Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
Mar, 2032

(7 years from now)

US9592208

(Pediatric)

NOVARTIS Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
Sep, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Strength(NS) May 11, 2021
New Patient Population(NPP) May 11, 2021
Pediatric Exclusivity(PED) Nov 11, 2021
M(M-106) Jul 20, 2014
New Chemical Entity Exclusivity(NCE) Sep 21, 2015

Drugs and Companies using FINGOLIMOD HYDROCHLORIDE ingredient

NCE-1 date: 11 November, 2020

Market Authorisation Date: 11 May, 2018

Treatment: Treatment of multiple sclerosis in the pediatric patient population with 0.25 mg fingolimod

Dosage: CAPSULE;ORAL

How can I launch a generic of GILENYA before it's drug patent expiration?
More Information on Dosage

GILENYA family patents

Family Patents

63. Gonitro patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9101592 POHL BOSKAMP Stabilized granules containing glyceryl trinitrate
Mar, 2032

(7 years from now)

Drugs and Companies using NITROGLYCERIN ingredient

Market Authorisation Date: 08 June, 2016

Treatment: NA

Dosage: POWDER;SUBLINGUAL

More Information on Dosage

GONITRO family patents

Family Patents

64. Harvoni patents expiration

HARVONI's oppositions filed in EPO
HARVONI IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9393256 GILEAD SCIENCES INC Methods for treating HCV
Sep, 2032

(8 years from now)

US10456414 GILEAD SCIENCES INC Methods for treating HCV
Sep, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-136) Apr 07, 2024
ODE*(ODE*) Apr 07, 2024
Pediatric Exclusivity(PED) Oct 07, 2024
Orphan Drug Exclusivity(ODE) Apr 07, 2024
New Chemical Entity Exclusivity(NCE) Oct 10, 2019
New Dosing Schedule(D-158) Feb 12, 2019
New Dosing Schedule(D-159) Feb 12, 2019
New Dosing Schedule(D-160) Feb 12, 2019
New Patient Population(NPP) Apr 07, 2020
New Indication(I-718) Nov 12, 2018
New Dosing Schedule(D-153) Nov 12, 2018
New Indication(I-719) Nov 12, 2018
New Indication(I-720) Nov 12, 2018
New Dosing Schedule(D-177) Nov 15, 2022

Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient

NCE-1 date: 08 October, 2023

Market Authorisation Date: 28 August, 2019

Treatment: For the treatment of hepatitis c

Dosage: TABLET;ORAL; PELLETS;ORAL

More Information on Dosage

HARVONI family patents

Family Patents

65. Hepzato patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11633528 DELCATH SYSTEMS INC Apparatus for removing chemotherapy compounds from blood
Nov, 2032

(8 years from now)

US10098997 DELCATH SYSTEMS INC Apparatus for removing chemotherapy compounds from blood
Nov, 2032

(8 years from now)

US10369264 DELCATH SYSTEMS INC Apparatus for removing chemotherapy compounds from blood
Nov, 2032

(8 years from now)

US10569004 DELCATH SYSTEMS INC Apparatus for removing chemotherapy compounds from blood
Nov, 2032

(8 years from now)

US11241522 DELCATH SYSTEMS INC Apparatus for removing chemotherapy compounds from blood
Nov, 2032

(8 years from now)

US11833286 DELCATH SYSTEMS INC Filter and frame apparatus and method of use
Dec, 2032

(8 years from now)

US11083831 DELCATH SYSTEMS INC Filter and frame apparatus and method of use
Dec, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 14, 2026
Orphan Drug Exclusivity(ODE-438) Aug 14, 2030

Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient

Market Authorisation Date: 14 August, 2023

Treatment: A percutaneous hepatic perfusion procedure for treating a patient with uveal melanoma with unresectable hepatic metastases; A method of treating a patient with uveal melanoma with unresectable hepatic...

Dosage: POWDER;INTRA-ARTERIAL

More Information on Dosage

HEPZATO family patents

Family Patents

66. Ilevro patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8921337 HARROW EYE Carboxyvinyl polymer-containing nanoparticle suspensions
Mar, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 16, 2015

Drugs and Companies using NEPAFENAC ingredient

Market Authorisation Date: 16 October, 2012

Treatment: NA

Dosage: SUSPENSION/DROPS;OPHTHALMIC

How can I launch a generic of ILEVRO before it's drug patent expiration?
More Information on Dosage

ILEVRO family patents

Family Patents

67. Imvexxy patents expiration

IMVEXXY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10806697 MAYNE PHARMA Vaginal inserted estradiol pharmaceutical compositions and methods
Nov, 2032

(8 years from now)

US9289382 MAYNE PHARMA Vaginal inserted estradiol pharmaceutical compositions and methods
Nov, 2032

(8 years from now)

US11304959 MAYNE PHARMA Vaginal inserted estradiol pharmaceutical compositions and methods
Nov, 2032

(8 years from now)

US11351182 MAYNE PHARMA Vaginal inserted estradiol pharmaceutical compositions and methods
Nov, 2032

(8 years from now)

US11497709 MAYNE PHARMA Vaginal inserted estradiol pharmaceutical compositions and methods
Nov, 2032

(8 years from now)

US10835487 MAYNE PHARMA Vaginal inserted estradiol pharmaceutical compositions and methods
Nov, 2032

(8 years from now)

US11241445 MAYNE PHARMA Vaginal inserted estradiol pharmaceutical compositions and methods
Nov, 2032

(8 years from now)

US11246875 MAYNE PHARMA Vaginal inserted estradiol pharmaceutical compositions and methods
Nov, 2032

(8 years from now)

US10537581 MAYNE PHARMA Vaginal inserted estradiol pharmaceutical compositions and methods
Nov, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 29, 2021

Drugs and Companies using ESTRADIOL ingredient

Market Authorisation Date: 29 May, 2018

Treatment: Treatment of a symptom of vulvar and vaginal atrophy; Treatment of dyspareunia

Dosage: INSERT;VAGINAL

How can I launch a generic of IMVEXXY before it's drug patent expiration?
More Information on Dosage

IMVEXXY family patents

Family Patents

68. Inbrija patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8685442 ACORDA Capsules containing high doses of levodopa for pulmonary use
Nov, 2032

(8 years from now)

US8945612 ACORDA Capsules containing high doses of levodopa for pulmonary use
Nov, 2032

(8 years from now)

US8545878 ACORDA Capsules containing high doses of levodopa for pulmonary use
Nov, 2032

(8 years from now)

US9393210 ACORDA Capsules containing high doses of levodopa for pulmonary use
Nov, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 21, 2021

Drugs and Companies using LEVODOPA ingredient

Market Authorisation Date: 21 December, 2018

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

INBRIJA family patents

Family Patents

69. Inrebic patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10391094 BRISTOL-MYERS Compositions and methods for treating myelofibrosis
Jun, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-259) Aug 16, 2026
New Chemical Entity Exclusivity(NCE) Aug 16, 2024

Drugs and Companies using FEDRATINIB HYDROCHLORIDE ingredient

NCE-1 date: 17 August, 2023

Market Authorisation Date: 16 August, 2019

Treatment: Treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis

Dosage: CAPSULE;ORAL

More Information on Dosage

INREBIC family patents

Family Patents

70. Ionsys patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8781571 THE MEDICINES CO Switch validation circuit and method
Mar, 2032

(7 years from now)

US8428708 THE MEDICINES CO Self-test for analgesic product
May, 2032

(7 years from now)

US8428709 THE MEDICINES CO Current control for electrotransport drug delivery
Jun, 2032

(8 years from now)

Drugs and Companies using FENTANYL HYDROCHLORIDE ingredient

Market Authorisation Date: 22 May, 2006

Treatment: Method for iontophoretic transdermal delivery of fentanyl hydrochloride

Dosage: SYSTEM;IONTOPHORESIS, TRANSDERMAL

More Information on Dosage

IONSYS family patents

Family Patents

71. Isentress Hd patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10772888 MSD SUB MERCK Solid pharmaceutical compositions containing an integrase inhibitor
Mar, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Strength(NS) May 26, 2020
New Dosing Schedule(D-167) May 26, 2020
New Patient Population(NPP) Dec 21, 2014
Pediatric Exclusivity(PED) May 22, 2021
M(M-114) Mar 28, 2015
New Chemical Entity Exclusivity(NCE) Oct 12, 2012

Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient

NCE-1 date: 22 May, 2020

Market Authorisation Date: 12 October, 2007

Treatment: Treatment of hiv-1 infection

Dosage: TABLET;ORAL

How can I launch a generic of ISENTRESS HD before it's drug patent expiration?
More Information on Dosage

ISENTRESS HD family patents

Family Patents

72. Joenja patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8653092 PHARMING Tetrahydro-pyrido-pyrimidine derivatives
Feb, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-430) Mar 24, 2030
New Chemical Entity Exclusivity(NCE) Mar 24, 2028

Drugs and Companies using LENIOLISIB PHOSPHATE ingredient

NCE-1 date: 25 March, 2027

Market Authorisation Date: 24 March, 2023

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

JOENJA family patents

Family Patents

73. Jornay Pm patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8927010 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

US9028868 IRONSHORE PHARMS Methods and compositions for treatment of attention deficit disorder
Mar, 2032

(7 years from now)

US9034902 IRONSHORE PHARMS Methods for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

US8916588 IRONSHORE PHARMS Methods for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

US9603809 IRONSHORE PHARMS Methods of treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

US10292937 IRONSHORE PHARMS Methods of treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

US10617651 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

US10881618 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

US11911518 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

US9023389 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

US11241391 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

US11241392 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

US10182995 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

US10905652 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

US9498447 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

US9283214 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 08, 2021

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Market Authorisation Date: 08 August, 2018

Treatment: Method of treating attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage

JORNAY PM family patents

Family Patents

74. Korlym patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10842801 CORCEPT THERAP Optimizing mifepristone absorption
Nov, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-22) Feb 17, 2019
New Product(NP) Feb 17, 2015
Orphan Drug Exclusivity(ODE) Feb 17, 2019

Drugs and Companies using MIFEPRISTONE ingredient

Market Authorisation Date: 17 February, 2012

Treatment: Treating cushing's syndrome

Dosage: TABLET;ORAL

How can I launch a generic of KORLYM before it's drug patent expiration?
More Information on Dosage

KORLYM family patents

Family Patents

75. Kuvan patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9216178 BIOMARIN PHARM Dry blend formulation of tetrahydrobiopterin
Nov, 2032

(8 years from now)

Drugs and Companies using SAPROPTERIN DIHYDROCHLORIDE ingredient

Market Authorisation Date: 19 December, 2013

Treatment: NA

Dosage: POWDER;ORAL

How can I launch a generic of KUVAN before it's drug patent expiration?
More Information on Dosage

KUVAN family patents

Family Patents

76. Lazanda patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9731869 BTCP PHARMA Container
Jan, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Jun 30, 2014

Drugs and Companies using FENTANYL CITRATE ingredient

Market Authorisation Date: 30 June, 2011

Treatment: NA

Dosage: SPRAY, METERED;NASAL

More Information on Dosage

LAZANDA family patents

Family Patents

77. Levemir Flexpen patents expiration

LEVEMIR FLEXPEN's oppositions filed in EPO
LEVEMIR FLEXPEN IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265893 NOVO NORDISK INC Injection button
Sep, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-117) May 18, 2015
M(M-115) Apr 06, 2015

Drugs and Companies using INSULIN DETEMIR RECOMBINANT ingredient

Market Authorisation Date: 31 October, 2013

Treatment: NA

Dosage: INJECTABLE;SUBCUTANEOUS

More Information on Dosage

LEVEMIR FLEXPEN family patents

Family Patents

78. Levemir Flextouch patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9132239 NOVO NORDISK INC Dial-down mechanism for wind-up pen
Feb, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-117) May 18, 2015
M(M-115) Apr 06, 2015

Drugs and Companies using INSULIN DETEMIR RECOMBINANT ingredient

Market Authorisation Date: 31 October, 2013

Treatment: NA

Dosage: INJECTABLE;SUBCUTANEOUS

More Information on Dosage

LEVEMIR FLEXTOUCH family patents

Family Patents

79. Levothyroxine Sodium patents expiration

LEVOTHYROXINE SODIUM IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9168238 FRESENIUS KABI USA Levothyroxine formulations
Aug, 2032

(8 years from now)

US9168239 FRESENIUS KABI USA Levothyroxine formulations
Aug, 2032

(8 years from now)

US9006289 FRESENIUS KABI USA Levothyroxine formulations
Oct, 2032

(8 years from now)

Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Market Authorisation Date: 24 June, 2011

Treatment: NA

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of LEVOTHYROXINE SODIUM before it's drug patent expiration?
More Information on Dosage

LEVOTHYROXINE SODIUM family patents

Family Patents

80. Livmarli patents expiration

Can you believe LIVMARLI received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10512657 MIRUM Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
Oct, 2032

(8 years from now)

US11376251 MIRUM Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
Oct, 2032

(8 years from now)

US11229661 MIRUM Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
Oct, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 29, 2026
Orphan Drug Exclusivity(ODE-429) Mar 13, 2030
New Indication(I-938) Mar 13, 2027
Orphan Drug Exclusivity(ODE-379) Sep 29, 2028
New Patient Population(NPP) Mar 13, 2026
Orphan Drug Exclusivity(ODE-471) Mar 13, 2031

Drugs and Companies using MARALIXIBAT CHLORIDE ingredient

NCE-1 date: 29 September, 2025

Market Authorisation Date: 29 September, 2021

Treatment: Treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestatis (pfic); Treatment of cholestatic pruritus in patients with alagille syndrome (algs)

Dosage: SOLUTION;ORAL

More Information on Dosage

LIVMARLI family patents

Family Patents

81. Livtencity patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11684632 TAKEDA PHARMS USA Maribavir isomers, compositions, methods of making and methods of using
Jan, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 23, 2026
Orphan Drug Exclusivity(ODE-388) Nov 23, 2028

Drugs and Companies using MARIBAVIR ingredient

NCE-1 date: 23 November, 2025

Market Authorisation Date: 23 November, 2021

Treatment: Treatment of patients with post-transplant cytomegalovirus (cmv) infection/disease refractory to treatment with ganciclovir, valganciclovir, cidofovir, or foscarnet, where the patient is a stem cell, ...

Dosage: TABLET;ORAL

More Information on Dosage

LIVTENCITY family patents

Family Patents

82. Lokelma patents expiration

LOKELMA's oppositions filed in EPO